Overview

A Study in Benign Prostatic Hyperplasia

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured by resistive index (RI) in the prostate transition zone.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Tadalafil